Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2

Interventions

Prednisone 112Docetaxel 87Leuprolide 79enzalutamide 72Abiraterone Acetate 67bicalutamide 53Goserelin 50acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 42Radiotherapy 39abiraterone 28Magnetic Resonance Spectroscopy 27Gonadotropin-Releasing Hormone 24gallium 68 PSMA-11 23apalutamide 22Androgen Antagonists 22luprolide acetate gel depot 21sipuleucel-T 20Radiosurgery 20Triptorelin Pamoate 18cabazitaxel 17cabozantinib 16Radiotherapy, Intensity-Modulated 16Flutamide 16pembrolizumab 15radium Ra 223 dichloride 14Prednisolone 14Nivolumab 14Dutasteride 14Dexamethasone 14Radiation 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Prostatic Neoplasms × Prostate-Specific Antigen × Clear all
NCT02933255 2024-05-31

PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
24 enrolled 20 charts
Genitourinary

Prostatic Neoplasms

NCT02710422 2019-09-11

MMEP

University of Miami

Phase 2 Terminated
24 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡